Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JPMA to Present Proposals for Industry Promotion
February 1, 2010
- GLP-1 Analogues to Be Recommended for Severe DM
February 1, 2010
- Teva-Kowa Acquires 2/3 of Taisho Pharm's Shares
February 1, 2010
- NIHS's Working Group Finds No Problems with Generics of 9 APIs
February 1, 2010
- Sciele Pharma Renamed Shionogi Pharma
February 1, 2010
- EPO's Biosimilar Approved: JCR, Kissei
February 1, 2010
- Kyowa Kirin Revises Business Forecasts Downward
February 1, 2010
- JGA President Expresses Hope for the New Pricing System
February 1, 2010
- Iwaki Posts Net Losses Two Years in a Row
February 1, 2010
- High Out-of-Pocket Expenses Cited by 38.4% of Households Not Seeing Doctor
February 1, 2010
- 29 Products Approved Including Japan's 1st GLP-1 Analogue
February 1, 2010
- Ethical Drugs Show Double-Digit Growth for the First Time in FY2009: Crecon
February 1, 2010
- Japan's 1st GLP-1 Analogue Victoza: Novo Nordisk
February 1, 2010
- JSMI Recommends 29 More APIs for Switching to OTC Status
February 1, 2010
- Combination of ARB + Ca Blocker Rezaltas: Daiichi Sankyo
February 1, 2010
- Humira, Remicade to Be Excluded from DPC Payment When Used for Psoriasis
February 1, 2010
- Notification Issued for Proper Use of Afinitor
February 1, 2010
- Higher-Strength Metformin Preparation Metgluco Tab 250 mg: DSP
February 1, 2010
- Remicade for Psoriasis: MTPC
February 1, 2010
- Bendamustine Added to NCCN GLs as First-Line Therapy: SymBio
February 1, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…